When will the ALCAINE patents expire, and when will generic ALCAINE be available?

Sponsor	Phase
Buddhist Tzu Chi General Hospital	Early Phase 1
Louisiana State University Health Sciences Center in New Orleans	Phase 4
William Beaumont Hospitals	Phase 4

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ALCAINE	proparacaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	080027-001	Approved Prior to Jan 1, 1982	AT	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 18, 2026

ALCAINE is Alcon’s branded proparacaine hydrochloride ophthalmic solution, primarily used as a topical ocular anesthetic for short ophthalmic procedures and diagnostic examinations. Its commercial position is mature: core FDA exclusivity and patent barriers have expired, generic proparacaine products compete directly, and Alcon does not separately report ALCAINE revenue. The product’s financial trajectory is therefore more closely linked to procedure volumes, ophthalmology channel access, supply reliability, and brand retention than to regulatory exclusivity.

What is ALCAINE and how is it used?

ALCAINE contains proparacaine hydrochloride 0.5% in an ophthalmic solution. It is administered topically to temporarily anesthetize the eye before procedures such as tonometry, foreign-body removal, and other short diagnostic or surgical interventions (Alcon Laboratories, 2023).

Product	Active ingredient	Strength	Dosage form	Primary use	Commercial owner
ALCAINE	Proparacaine hydrochloride	0.5%	Sterile ophthalmic solution	Topical ocular anesthesia	Alcon
Generic proparacaine	Proparacaine hydrochloride	Commonly 0.5%	Ophthalmic solution	Same	Multiple generic manufacturers

ALCAINE is distinct from longer-acting ophthalmic anesthetics and from anesthetic products used for major ophthalmic surgery. Its demand is tied to routine eye examinations, ophthalmic diagnostics, emergency eye care, and ambulatory procedures.

What is the FDA regulatory status of ALCAINE?

ALCAINE is an FDA-approved prescription ophthalmic product. The product is identified in FDA labeling as proparacaine hydrochloride ophthalmic solution USP, 0.5% (U.S. Food and Drug Administration [FDA], n.d.-a).

The relevant regulatory characteristics are:

Regulatory issue	ALCAINE status
FDA pathway	Full NDA product
NDA	016654
Active ingredient	Proparacaine hydrochloride
Route	Ophthalmic
Prescription status	Prescription drug
Regulatory category	Small-molecule ophthalmic anesthetic
Reference-product relevance	Generic manufacturers may rely on the reference product under an ANDA pathway
Biologic status	Not a biologic

The product has been marketed for decades. Its age means that the principal competitive issues are manufacturing consistency, sterile supply, distribution, and physician familiarity rather than clinical differentiation.

What patents protect ALCAINE?

No meaningful current patent moat is publicly associated with ALCAINE’s original active ingredient, basic 0.5% ophthalmic formulation, or long-standing clinical use. Proparacaine is an established small molecule, and the commercial product has been available for many years.

The relevant intellectual-property assessment is:

IP category	Current competitive significance
Proparacaine composition patent	Expired
Basic 0.5% ophthalmic solution claims	Any original protection is expired or commercially ineffective
Method-of-use protection	No material current barrier identified for routine topical anesthesia
Formulation patents	No publicly established blocking patent estate for conventional ALCAINE
Manufacturing know-how	Potentially relevant, but not an exclusivity right
Trademark	ALCAINE brand remains commercially relevant, subject to trademark law

FDA’s Orange Book is the principal source for listed patents and exclusivity associated with approved drugs. The Orange Book does not create market exclusivity by itself; it records approved-product information and applicable patent or exclusivity data (FDA, n.d.-b).

When does ALCAINE lose exclusivity?

ALCAINE’s core regulatory and patent exclusivity has already expired. There is no commercially relevant future loss-of-exclusivity event comparable to a modern branded drug approaching patent expiry.

Exclusivity type	ALCAINE position
New chemical entity exclusivity	Expired
Original composition protection	Expired
Pediatric exclusivity	No current commercial impact
Orphan-drug exclusivity	Not applicable
Data exclusivity	Expired
Current patent cliff	None
Generic competition	Established

The product’s remaining differentiation is brand-based. Alcon can retain demand through supply reliability, established purchasing contracts, packaging, quality controls, and ophthalmology distribution relationships.

How many patents cover ALCAINE?

The commercially important answer is that no active patent portfolio appears to block generic proparacaine ophthalmic competition. ALCAINE should be analyzed as a mature, off-patent product rather than as a drug with a defensible patent estate.

This does not mean that every historical patent related to proparacaine has identical legal status in every jurisdiction. It means that expired basic composition and formulation rights do not provide Alcon with a current U.S. barrier to approved generic products.

What is the Orange Book status of ALCAINE?

ALCAINE is an approved prescription drug listed through FDA drug-product records. The key Orange Book implication is the absence of a current, commercially material patent barrier that would prevent ANDA-based competition.

Generic applicants generally face the standard requirements for ophthalmic products:

Pharmaceutical equivalence to the reference product.
Bioequivalence or an applicable FDA-accepted equivalence approach.
Sterility and microbiological quality.
Container-closure compatibility.
Manufacturing controls for an ophthalmic solution.
Labeling consistent with the reference product, subject to FDA approval.

For a conventional topical ophthalmic solution, regulatory execution can be more important than molecule-level discovery. Sterile manufacturing failures, particulate contamination, preservative performance, container compatibility, and supply interruptions can affect market share.

Are there Paragraph IV challenges to ALCAINE?

Paragraph IV litigation is unlikely to be commercially central for ALCAINE because its foundational patents have expired and generic proparacaine products have long been available. Paragraph IV certifications matter when an ANDA applicant challenges an unexpired listed patent. The mature status of ALCAINE reduces the likelihood that a new entrant would need to litigate over the basic product.

No prominent current Paragraph IV dispute materially affecting ALCAINE is identified in the public record reviewed for this analysis. Generic applicants may still encounter FDA review issues, facility inspections, manufacturing deficiencies, or labeling disputes, but those are distinct from patent litigation.

What formulations are protected by ALCAINE?

ALCAINE is a conventional sterile ophthalmic solution containing proparacaine hydrochloride. Its formulation profile does not provide the type of differentiated delivery-system protection seen in sustained-release implants, depot injections, drug-eluting devices, or complex ophthalmic emulsions.

Potential formulation barriers are operational rather than exclusivity-based:

Sterile aqueous processing.
Preservative control.
pH and tonicity.
Container-closure integrity.
Dropper performance.
Stability through distribution.
Control of particulate matter.
Microbial limits and sterility assurance.

These requirements can limit the number of reliable suppliers, but they do not prevent competition after FDA approval.

Which companies compete with ALCAINE?

ALCAINE competes with generic proparacaine products and, in limited settings, alternative topical ophthalmic anesthetics.

Competitive category	Examples	Competitive effect
Generic proparacaine	FDA-approved generic 0.5% solutions	Direct price competition
Tetracaine ophthalmic	Alternative topical anesthetic	Procedure-specific substitution
Lidocaine-based ophthalmic products	Selected clinical settings	Alternative where formulation and duration differ
Institutionally purchased anesthetics	Hospital and ambulatory-care products	Tender and contract competition

Direct generic proparacaine competition is the principal threat. Hospital systems, group purchasing organizations, ophthalmology practices, and distributors can substitute among therapeutically equivalent products when price, availability, and contract terms favor another supplier.

How strong is the ALCAINE patent estate?

The patent estate is weak from a current commercial-protection perspective. ALCAINE’s defensibility rests on brand and execution rather than exclusivity.

Strength factor	Assessment
Active ingredient protection	Weak; mature and off patent
Formulation protection	Weak for the conventional solution
Method-of-use protection	Weak
Regulatory exclusivity	Expired
Brand recognition	Moderate within ophthalmology
Manufacturing complexity	Moderate because the product must be sterile
Switching costs	Low to moderate
Distribution position	Potentially important
Litigation leverage	Limited

The strongest practical barrier is not patent law. It is the ability to maintain consistent sterile supply and preserve preferred status in institutional and ophthalmology purchasing channels.

What is the financial trajectory of ALCAINE?

Alcon does not separately disclose ALCAINE revenue, gross margin, unit volume, or operating profit in its public financial reporting. The product is reported within broader ophthalmic and surgical portfolios, preventing a reliable product-level revenue series.

Alcon reported total sales of approximately $9.1 billion in 2022 and approximately $9.4 billion in 2023, with sales divided principally between Vision Care and Surgical products (Alcon Inc., 2024). ALCAINE is a small mature product within that larger portfolio and is not identified as a material standalone growth driver.

Financial factor	Likely impact on ALCAINE
Unit demand	Stable, linked to ophthalmic procedure volume
Price growth	Limited by generic competition
Revenue growth	More likely low or flat absent price or distribution changes
Margin profile	Pressured by generic pricing and sterile manufacturing costs
Brand premium	Possible in selected accounts
Supply interruption risk	Material because ophthalmic products require sterile production
Portfolio role	Complementary product within Alcon’s ophthalmic franchise
Financial materiality to Alcon	Not separately quantifiable from public disclosures

ALCAINE’s revenue trajectory is likely mature rather than expansionary. A stable installed base of ophthalmology practices can support recurring demand, but generic substitution limits pricing power. Revenue can also move with procedure volumes, hospital purchasing contracts, inventory cycles, and competitor shortages.

What generic entry risks exist for ALCAINE?

Generic entry is already an established market condition rather than a future event. The main commercial risks are:

Price compression from additional generic suppliers.
Loss of formulary or contract preference.
Distributor substitution.
Reduced physician sensitivity to brand selection.
Procurement-driven switching in hospitals and ambulatory surgery centers.
Product shortages that shift customers to alternative suppliers.
Manufacturing-cost inflation that cannot be passed through.

ALCAINE may retain customers when clinicians value established packaging, familiarity, consistent drop delivery, or confidence in supply. Those factors can slow substitution but rarely support a durable premium without contractual or clinical differentiation.

What patent litigation affects ALCAINE?

No major current patent litigation is identified as materially affecting ALCAINE’s U.S. commercial position. The absence of active litigation is consistent with the product’s mature, off-patent status.

The more relevant legal and compliance risks are:

FDA manufacturing inspections.
Product-quality investigations.
Sterility failures.
Recalls.
Labeling compliance.
Trademark enforcement.
Distribution and supply agreements.

These risks can affect sales quickly because ophthalmic products are purchased on availability and quality assurance as much as on brand preference.

Does ALCAINE face biosimilar risk?

No. ALCAINE is a small-molecule drug, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. Competition occurs through generic-drug pathways, primarily abbreviated new drug applications, rather than biosimilar applications.

How does ALCAINE compare with newer ophthalmic products?

ALCAINE has a lower innovation profile but a simpler commercial proposition than newer ophthalmic products.

Attribute	ALCAINE	Newer ophthalmic drug or device
Clinical role	Short-duration topical anesthesia	May provide sustained delivery or differentiated therapy
Patent position	Mature and largely expired	Often central to valuation
Regulatory risk	Established product profile	Higher clinical and regulatory risk
Price power	Limited	Potentially higher if differentiated
Market growth	Procedure-linked	Can expand through new indications
Manufacturing	Sterile conventional solution	May involve complex device or formulation technology

ALCAINE should not be valued using the framework applied to a protected specialty pharmaceutical. Its economic value is closer to that of a durable branded generic with an established ophthalmology channel.

What is the generic launch scenario for ALCAINE?

A new generic entrant would not create a single future patent cliff. Instead, entry would intensify an existing competitive market.

Base case

Generic proparacaine remains widely available, while ALCAINE maintains a smaller branded share through physician familiarity and distribution. Revenue is stable to modestly declining, with limited price growth.

Downside case

Additional generic capacity, a favorable hospital contract, or a temporary Alcon supply disruption accelerates conversion to lower-cost alternatives. ALCAINE loses volume and pricing.

Supply-constrained case

A generic shortage or manufacturing interruption supports temporary brand demand and improves ALCAINE’s volume. The benefit would likely reverse when generic supply normalizes.

What geographic coverage applies to ALCAINE?

ALCAINE’s regulatory and commercial position must be assessed country by country. U.S. FDA approval does not establish approval, patent status, or reimbursement treatment in Europe, Canada, Japan, or emerging markets.

In most jurisdictions, the active ingredient’s age limits composition-patent protection. Country-specific differences remain relevant for:

Marketing authorization.
Product naming.
Local generic approvals.
Manufacturing-site registration.
Import requirements.
Prescription classification.
Hospital tender access.
Trademark rights.
Reimbursement and procurement rules.

The United States is the most relevant market for Orange Book and ANDA analysis. International commercial performance depends more on local registration and distributor coverage than on U.S. patent rights.

Key Takeaways

ALCAINE is Alcon’s branded proparacaine hydrochloride 0.5% ophthalmic solution.
It is an FDA-approved, mature small-molecule product with expired foundational exclusivity.
No commercially meaningful active patent estate is apparent for the conventional product.
Generic competition is established, and Paragraph IV litigation is not a central current risk.
The product is not subject to biosimilar competition.
Alcon does not separately disclose ALCAINE revenue, margin, or unit volume.
Financial performance is driven by ophthalmic procedure volumes, institutional purchasing, distribution, brand retention, and sterile supply reliability.
ALCAINE’s valuation profile is that of a mature branded generic, not a patent-protected growth asset.
The main operational risks are price erosion, generic substitution, manufacturing quality, and supply disruption.

FAQs About ALCAINE Patent and Market Exposure

Is ALCAINE still patent protected?

No material current patent protection appears to block generic proparacaine competition in the United States. The original active-ingredient and conventional-product protection has expired.

Is ALCAINE a generic drug?

ALCAINE is a branded product. Generic manufacturers sell proparacaine ophthalmic solutions that compete with it therapeutically and commercially.

Does Alcon disclose ALCAINE sales?

No. Alcon reports broader Vision Care and Surgical financial results rather than standalone ALCAINE revenue.

Can hospitals substitute generic proparacaine for ALCAINE?

Yes. Hospitals and ophthalmology practices can generally use FDA-approved therapeutically equivalent products, subject to formulary, procurement, availability, and clinical policies.

What is the main investment risk for ALCAINE?

The main risk is gradual revenue and margin erosion from generic substitution, compounded by institutional price negotiations and potential sterile-product supply disruptions.

References

Alcon Inc. (2024). 2023 annual report. https://www.alcon.com/investors
Alcon Laboratories, Inc. (2023). ALCAINE (proparacaine hydrochloride ophthalmic solution USP, 0.5%) prescribing information.
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	6
Patent Applications:	964
DailyMed Link:	ALCAINE at DailyMed

Drug Class	Local Anesthetic
Physiological Effect	Local Anesthesia

ALCAINE Drug Patent Profile

Which patents cover Alcaine, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alcaine

AI Deep Research

Questions you can ask:

Summary for ALCAINE

Recent Clinical Trials for ALCAINE

Pharmacology for ALCAINE

US Patents and Regulatory Information for ALCAINE

ALCAINE Market Dynamics, Patent Status, Competition, and Financial Trajectory